12.09
Teclistamab Shows Higher Response Rates Than Standard Therapy in High-Risk Smoldering Myeloma
The randomized phase 2 ImmunoPRISM trial found that teclistamab produced more complete clinical responses than lenalidomide-dexamethasone in patients with high-risk smoldering multiple myel…